Pharmaceutical

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).

Apr 19, 2024 - 00:00
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).
Read the original article

Tags:

Previous Article

Rigosertib sodium by Traws Pharma for Epidermolysis Bullosa: Likelihood of Approval

Next Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

The next act for a biotech rainmaker

The next act for a biotech rainmaker

Feb 29, 2024

STAT+: Epic and Microsoft’s AI collaboration, Amazon and 3M, & Abbott’s CGM momentum

STAT+: Epic and Microsoft’s AI collaboration, Amazon an...

Apr 23, 2023

STAT+: Fiery MedPAC meeting highlights massive overpayments in Medicare Advantage

STAT+: Fiery MedPAC meeting highlights massive overpaym...

Jan 12, 2024